Special Issue

Pharmacology of Heart Failure

Message from the Guest Editors

Despite advances in the prevention and treatment of cardiovascular diseases, heart failure remains a major challenge in developed countries, and its economic and social burden is still increasing. Over the years, many pharmacological and interventional treatments for heart failure have been developed that have improved the quality of life and global life expectancy. A number of medications that are commonly used in clinical practice are relatively or absolutely contraindicated in patients with heart failure because they can cause exacerbations to this condition or have significant pharmacodynamic interactions with basic heart failure medications. This requires a holistic assessment of the patient and the meticulous management of medication regimens that are often complex. Our aim for this Special Issue is to offer our readers short but comprehensive, state-of-theart articles on the treatment of heart failure with regard to the pharmacokinetics and pharmacodynamics of drugs, drug interactions, adverse effects, and complex treatment regimens for comorbidities in heart failure.

Guest Editors

Dr. Wioletta Szczurek-Wasilewicz

- 1. Department of Pharmacology, Faculty of Medicine, University of Opole, Opole, Poland
- 2. 2nd Department of Cardiology and Angiology, Silesian Center for Heart Diseases, 41-800 Zabrze, Poland

Prof. Dr. Bożena Szyguła-Jurkiewicz

3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland

Deadline for manuscript submissions

31 December 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/222755

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

